Brief: Arrivent Biopharma Enters Exclusive License With Lepu Biopharma For Mrg007, An Antibody Drug Conjugate
22/01/2025 24:02
Jan 21 (Reuters) - Lepu Biopharma Co Ltd 2157.HK :
* ENTERS EXCLUSIVE LICENSE WITH LEPU BIOPHARMA FOR MRG007,
AN
ANTIBODY DRUG CONJUGATE FOR THE TREATMENT OF GASTROINTESTINAL
CANCERS
Source text: ID:nGNX8rlqWM
Further company coverage: 2157.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ArriVent BioPharma
See all newsBrief: Arrivent Announces First Patient Dosed With Novel Tetravalent Muc16/Napi2b Dual Target Adc, Arr-002
US RESEARCH ROUNDUP-Allstate, Caribou Biosciences, Zscaler
U.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
ArriVent falls after lung cancer drug misses late-stage trial goal